2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal Of The National Cancer Institute 2015, 107: djv179. PMID: 26113580, PMCID: PMC4651106, DOI: 10.1093/jnci/djv179.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBody Mass IndexBreast NeoplasmsCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymph NodesLymphatic MetastasisMiddle AgedNeoplasm Recurrence, LocalPaclitaxelReceptors, EstrogenTreatment OutcomeConceptsBody mass indexBaseline body mass indexNode-positive breast cancerBreast cancerCALGB 9741Prognostic factorsMass indexMedian baseline body mass indexSignificant prognostic factorsIndependent prognostic factorBreast cancer outcomesGroup of patientsSequence of chemotherapyEstrogen receptor statusProportional hazards regressionActual body weightDose densityDosed chemotherapyMenopausal statusOverall survivalReceptor statusRandomized trialsHazards regressionPoor prognosisTumor size
2013
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Martín M, Prat A, Rodríguez-Lescure Á, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research And Treatment 2013, 138: 457-466. PMID: 23423445, PMCID: PMC3608881, DOI: 10.1007/s10549-013-2416-2.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell ProliferationClinical Trials, Phase III as TopicCyclophosphamideEpirubicinFemaleFluorouracilHumansKaplan-Meier EstimateKi-67 AntigenMiddle AgedMulticenter Studies as TopicMultivariate AnalysisPaclitaxelProportional Hazards ModelsProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeConceptsGroup of patientsWeekly paclitaxelOverall survivalPAM50 subtypesProliferation scoreBreast cancerNode-positive operable breast cancerMultivariable Cox regression analysisLow proliferation statusAnthracycline-containing chemotherapyOperable breast cancerPhase III trialsSubset of patientsCox regression analysisClinical-pathological variablesFEC armMedian followAdjuvant therapySecondary endpointsIII trialsPathological variablesHistologic gradeClinical trialsAdjuvant FECKi-67
2004
CNS metastases in breast cancer.
Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. Journal Of Clinical Oncology 2004, 22: 3608-17. PMID: 15337811, DOI: 10.1200/jco.2004.01.175.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyBreast cancerCNS metastasesStereotactic radiosurgeryProportion of patientsMetastatic breast cancerGroup of patientsSingle brain metastasisBrain metastasesCNS involvementMultiple metastasesNeurologic symptomsSystemic therapyMedical therapyAppropriate therapyCase seriesClinical presentationRandomized trialsRetrospective seriesCase reportSolid tumorsMetastasisPatientsCancerRoutine use
2003
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal Of Clinical Oncology 2003, 21: 999-1006. PMID: 12637463, DOI: 10.1200/jco.2003.05.068.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBexaroteneBreast NeoplasmsDisease ProgressionDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEstrogen Receptor ModulatorsFemaleHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneSurvival AnalysisTamoxifenTetrahydronaphthalenesThyroid HormonesToremifeneTreatment OutcomeConceptsMetastatic breast cancerTamoxifen-resistant patientsPartial responseStable diseaseBreast cancerOral bexaroteneAdverse eventsCommon drug-related adverse eventsDrug-related serious adverse eventsDrug-related adverse eventsMulticenter phase II studyRefractory metastatic breast cancerRetinoid X receptor-selective retinoidEfficacy of bexarotenePhase II studySerious adverse eventsChemotherapy-refractory patientsGroup of patientsReceptor-selective retinoidsHormone-refractory patientsTreatment of patientsCases of pancreatitisDrug-related deathsPreclinical antitumor activityOral agents